Idec Pharmaceuticals Corporation

San Diego, CA 92121

SBIR Award Summary

Total Number of Awards 27
Total Value of Awards $0.0
First Award Date 08/01/88
Most Recent Award Date 05/01/99

Key Personnel

Last Name Name Awards Contact
Morrow William John Morrow 3
Raychaudhuri Syamal Raychaudhuri 3
Miller Richard A Miller 3
Sobol Robert E Sobol 1
Kohler Heinz Kohler 2
Kang Chang-Yuil Kang 3
Newman Roland A Newman 1
Black Amelia A Black 3
Brams Peter Brams 5
Hariharan Kandasamy Hariharan 2
Noelle Randolph J. Noelle 1

27 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/99 - 10/31/99

Our long term objective is to develop tetravalent IgG/IgG monoclonal antibody dimers for treating leukemia and lymphoma patients over-expressing the CD23 membrane antigens. Preliminary data using both CD20 and CD23 B-cell membrane antigens has clearly demonstrated that hyper-cross linking induces both apoptosis and growth inhibition. In contra...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/98 - 09/29/99

DESCRIPTION: (Adapted from the applicant's abstract) CD40 and its ligand, CD154, have been shown to play an integral role in the regulation of cell- mediated immunity. As a result of interfering with antigen presenting cell function and diminishing inflammatory responses, anti-CD154 can ablate the immune respo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/98 - 08/31/99

An antibody specific for human gp39 is being developed to use in the treatment of autoimmune diseases, such as systemic lupus erythematosis, idiopathic thrombocytopenia purpura, multiple sclerosis and rheumatoid arthritis. In addition, the anti-gp39 antibody may have significant therapeutic value in pr...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 08/31/98

An antibody specific for human gp39 is being developed to use in the treatment of autoimmune diseases, such as systemic lupus erythematosis, idiopathic thrombocytopenia purpura, multiple sclerosis and rheumatoid arthritis. In addition, the anti-gp39 antibody may have significant therapeutic value in pr...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/97 - 04/30/99

We propose to clone, express, in vitro characterize and perform preclinical testing of two human monoclonal IgG1, kappa, antibodies, RF-1 and RF-2, that binds specifically and with high affinity to the fusion protein of the human Respiratory Syncytial Virus (RSV). The antibodies have in vitro virus neutralizing acti...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/96 - 02/28/97

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/96 - 04/30/97

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/95 - 01/31/96

DESCRIPTION: (From the applicant's abstract) "Infection with human papillovamirus (HPV) type l6 is strongly associated with the development of cervical and other ano-genital carcinomas. In more than 90 percent of cervical carcinomas HPV DNA can be detected. In ano-genital carcinoma biopsies, the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/15/94 - 03/14/95

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/93 - 03/31/94

DESCRIPTION: (Adapted from the applicant's abstract) Passive immunotherapy has been shown to be an effective method for controlling RSV infection. The virus envelope fusion (F protein) represents an ideal target for passive immunotherapy since antibodies to this protein typically bind to and neutralize both of the two clinical subgroups of...

Load More